FY25 interims are in line with full-year forecasts, with cash of circa £7.5m at April year end. Ilika has made stellar progress commercialising its solid-state-battery ‘SSB’ technology in both micro Stereax™ for miniature medical device markets and larger Goliath for EV application formats. Stereax, via US production and licensee partner Cirtec medical, is set-up to deliver first commercial revenues in CY25 while the Goliath program targets a minimum viable product ‘MVP’ for EV application in CY25 and the associated intensification of automotive OEM licensing interest.